title: Vaccine history knowledge of subcutaneous anti-TNF receiving rheumatology patients.
authors.forename: T J
authors.initials: TJ
authors.lastname: Nolan
authors.forename: Mortimer B
authors.initials: MB
authors.lastname: O'Connor
authors.forename: Ursula
authors.initials: U
authors.lastname: Bond
authors.forename: Joan
authors.initials: J
authors.lastname: Swan
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Phelan
mesh_terms: D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004333:Drug Administration Routes; D000068800:Etanercept; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D011939:Mental Recall; D010353:Patient Education as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D012216:Rheumatic Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014611:Vaccination
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D000068800:Etanercept